Question · Q4 2025
Wilma Burdis asked about the sustainability of CNO's strong 2025 growth, inquiring if there were unusual factors or potential upside from Medicare Advantage issues and tech investments. She also asked about the impact of Medicare Advantage distribution fees due to churn and if this is reflected in the 2026 outlook. Later, she inquired about investment universe dynamics influencing a shift to higher-yielding assets and any elevated sales benefit for annuities from increased Medicare supplement sales.
Answer
CEO Gary Bhojwani discussed product-specific expectations, anticipating decreased Medicare Advantage sales but increased Medicare supplement sales. He confirmed that expected Medicare Advantage volume is reflected in projections and that CNO prefers Medicare Supplement operationally due to control and cross-sell potential. CIO Eric Johnson explained that the investment strategy continues to focus on portfolio quality with tactical yield add-ins, not expecting changes to risk parameters due to tight spreads. Gary Bhojwani noted that while strong Medicare supplement sales help annuity cross-sells, it's mainly normal course growth.
Ask follow-up questions
Fintool can predict
CNO's earnings beat/miss a week before the call